Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Worldwide antibiotic resistance dynamics: how different is it from one drug-bug pair to another?

Eve Rahbe, Laurence Watier, Didier Guillemot, Philippe Glaser, Lulla Opatowski
doi: https://doi.org/10.1101/2022.02.09.22270726
Eve Rahbe
1Institut Pasteur, Epidemiology and Modelling of Antimicrobials Evasion (EMEA) research unit, Paris, France
2Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology research team, Montigny-Le-Bretonneux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: eve.rahbe@pasteur.fr
Laurence Watier
1Institut Pasteur, Epidemiology and Modelling of Antimicrobials Evasion (EMEA) research unit, Paris, France
2Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology research team, Montigny-Le-Bretonneux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didier Guillemot
1Institut Pasteur, Epidemiology and Modelling of Antimicrobials Evasion (EMEA) research unit, Paris, France
2Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology research team, Montigny-Le-Bretonneux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Glaser
3Institut Pasteur, Ecology and Evolution of Antibiotic Resistance research unit, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lulla Opatowski
1Institut Pasteur, Epidemiology and Modelling of Antimicrobials Evasion (EMEA) research unit, Paris, France
2Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology research team, Montigny-Le-Bretonneux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background Antibiotic resistance (ABR) is a major concern for global health. However, factors driving its emergence and dissemination are not fully understood. Identification of such factors is crucial to explain heterogeneity in ABR rates observed across space, time and species and antibiotics.

Methods We analyzed count data of resistant isolates from 51 countries over 2006-2019 for nine drug-bug pairs from the surveillance database ATLAS. We characterized ABR spatial and temporal patterns and used a mixed-effect negative binomial model, accounting for country-year dependences with random effects (RE), to investigate associations with potential drivers including antibiotic sales, economic and health indicators, meteorological data, population density and tourism.

Findings ABR patterns were strongly country and drug-bug pair dependent. In 2019, median ABR rates ranged from 6·3% for carbapenem-resistant (CR) Klebsiella pneumoniae to 72·3% for CR-Acinetobacter baumannii, with heterogeneity across countries (up to 50·2% of interquartile range for CR-A. baumannii). Over 2006-2019, carbapenem resistance was on the rise in >75% of investigated countries but no global trend was observed for other resistances. Multivariable analyses identified significant associations of ABR with antibiotic sales, but only in fluoroquinolone-resistant Escherichia coli, CR-A. baumannii and penicillin-resistant Streptococcus pneumoniae; with temperature in investigated Enterobacterales but not in other drug-bug pairs; and with the health system quality for most drug-bug pairs, except in Enterococci and S. pneumoniae. Despite wide consideration of possible explanatory variables, drug-bug pairs still showed high spatial RE variance.

Interpretation These results reflect the diversity found among human bacterial pathogens and stress the difficulty to generalize global antibiotic resistance findings.

Funding Independent research Pfizer Global Medical Grant; ANR Labex IBEID (ANR-10-LABX-62)

Competing Interest Statement

ER work was funded by an independent research Pfizer Global Medical Grant (number 57504809). PG and LW received consulting fees from Pfizer for an unrelated project. LW received consulting fees from HEVA and IQVIA for unrelated projects.

Funding Statement

Funding: Independent research Pfizer Global Medical Grant; ANR Labex IBEID (ANR-10-LABX-62)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The antibiotic resistance data can be visualized through the ATLAS website (https://atlas-surveillance.com). Co-variables data are publicly available through the World Bank Data website (https://data.worldbank.org); the Global Health Security index website (https://www.ghsindex.org); the Solar Radiation and Meteorological Data services website (http://www.soda-pro.com) for the MERRA-2 data; the ECDC website (https://www.ecdc.europa.eu/en/antimicrobial-consumption/surveillance-and-disease-data/database) for the ESAC-Net data. IQVIA MIDAS data are not publicly available. R codes to describe country-year longitudinal resistance data for an antibiotic-bacterium pair of interest and quantify its association with candidate factors are available here: https://github.com/EveRah/drug_bug_pair_NBMM.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 09, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Worldwide antibiotic resistance dynamics: how different is it from one drug-bug pair to another?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Worldwide antibiotic resistance dynamics: how different is it from one drug-bug pair to another?
Eve Rahbe, Laurence Watier, Didier Guillemot, Philippe Glaser, Lulla Opatowski
medRxiv 2022.02.09.22270726; doi: https://doi.org/10.1101/2022.02.09.22270726
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Worldwide antibiotic resistance dynamics: how different is it from one drug-bug pair to another?
Eve Rahbe, Laurence Watier, Didier Guillemot, Philippe Glaser, Lulla Opatowski
medRxiv 2022.02.09.22270726; doi: https://doi.org/10.1101/2022.02.09.22270726

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9778)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2314)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (505)
  • Infectious Diseases (except HIV/AIDS) (11653)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (697)
  • Pharmacology and Therapeutics (301)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2186)
  • Public and Global Health (4668)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)